Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer

Shuhei Ito, Eiji Oki, Yuichiro Nakashima, Koji Ando, Yukiharu Hiyoshi, Kippei Ohgaki, Hiroshi Saeki, Masaru Morita, Yoshihisa Sakaguchi, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

14 引用 (Scopus)

抄録

Background: More effective treatment is necessary to improve the poor prognosis for patients with unresectable gastric cancer. We investigated the efficacy and feasibility of adjuvant surgery following chemotherapy.

Patients and Methods: Records of 70 patients with unresectable stage IV gastric cancer who underwent induction chemotherapy were reviewed retrospectively. Patients who developed an absence of non-curative clinical factors during chemotherapy underwent gastrectomy [adjuvant surgery (AS) group]; the others continued chemotherapy [non-AS group].

Results: Non-AS and AS groups contained 56 (80%) and 14 (20%) patients, respectively. In the AS group, 92.9% of patients had one noncurative clinical factor, while 48.2% of patients in the non-AS group had two or more non-curative clinical factors (p=0.0386). In the AS group, operative outcomes, including the postoperative complication rate (21.4%), were acceptable. The 3-year overall survival rate in the AS group was 65.6% versus 7.7% in the non-AS group (p<0.0001). In patients with one noncurative clinical factor of peritoneal dissemination, the median survival of the AS group was 29.5 months versus 11.4 months in the non-AS group (p=0.0230).

Conclusion: Adjuvant surgery for initially unresectable stage IV gastric cancer was safe and feasible, and may improve the prognosis for patients with one non-curative clinical factor, such as peritoneal dissemination.

元の言語英語
ページ(範囲)401-406
ページ数6
ジャーナルAnticancer research
35
発行部数1
出版物ステータス出版済み - 1 1 2015

Fingerprint

Stomach Neoplasms
Drug Therapy
Induction Chemotherapy
Gastrectomy
Adjuvant Chemotherapy
Survival Rate
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. / Ito, Shuhei; Oki, Eiji; Nakashima, Yuichiro; Ando, Koji; Hiyoshi, Yukiharu; Ohgaki, Kippei; Saeki, Hiroshi; Morita, Masaru; Sakaguchi, Yoshihisa; Maehara, Yoshihiko.

:: Anticancer research, 巻 35, 番号 1, 01.01.2015, p. 401-406.

研究成果: ジャーナルへの寄稿記事

Ito, S, Oki, E, Nakashima, Y, Ando, K, Hiyoshi, Y, Ohgaki, K, Saeki, H, Morita, M, Sakaguchi, Y & Maehara, Y 2015, 'Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer', Anticancer research, 巻. 35, 番号 1, pp. 401-406.
Ito, Shuhei ; Oki, Eiji ; Nakashima, Yuichiro ; Ando, Koji ; Hiyoshi, Yukiharu ; Ohgaki, Kippei ; Saeki, Hiroshi ; Morita, Masaru ; Sakaguchi, Yoshihisa ; Maehara, Yoshihiko. / Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. :: Anticancer research. 2015 ; 巻 35, 番号 1. pp. 401-406.
@article{7dada24ef09946cd8f2fed70e83a0222,
title = "Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer",
abstract = "Background: More effective treatment is necessary to improve the poor prognosis for patients with unresectable gastric cancer. We investigated the efficacy and feasibility of adjuvant surgery following chemotherapy.Patients and Methods: Records of 70 patients with unresectable stage IV gastric cancer who underwent induction chemotherapy were reviewed retrospectively. Patients who developed an absence of non-curative clinical factors during chemotherapy underwent gastrectomy [adjuvant surgery (AS) group]; the others continued chemotherapy [non-AS group].Results: Non-AS and AS groups contained 56 (80{\%}) and 14 (20{\%}) patients, respectively. In the AS group, 92.9{\%} of patients had one noncurative clinical factor, while 48.2{\%} of patients in the non-AS group had two or more non-curative clinical factors (p=0.0386). In the AS group, operative outcomes, including the postoperative complication rate (21.4{\%}), were acceptable. The 3-year overall survival rate in the AS group was 65.6{\%} versus 7.7{\%} in the non-AS group (p<0.0001). In patients with one noncurative clinical factor of peritoneal dissemination, the median survival of the AS group was 29.5 months versus 11.4 months in the non-AS group (p=0.0230).Conclusion: Adjuvant surgery for initially unresectable stage IV gastric cancer was safe and feasible, and may improve the prognosis for patients with one non-curative clinical factor, such as peritoneal dissemination.",
author = "Shuhei Ito and Eiji Oki and Yuichiro Nakashima and Koji Ando and Yukiharu Hiyoshi and Kippei Ohgaki and Hiroshi Saeki and Masaru Morita and Yoshihisa Sakaguchi and Yoshihiko Maehara",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "35",
pages = "401--406",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer

AU - Ito, Shuhei

AU - Oki, Eiji

AU - Nakashima, Yuichiro

AU - Ando, Koji

AU - Hiyoshi, Yukiharu

AU - Ohgaki, Kippei

AU - Saeki, Hiroshi

AU - Morita, Masaru

AU - Sakaguchi, Yoshihisa

AU - Maehara, Yoshihiko

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: More effective treatment is necessary to improve the poor prognosis for patients with unresectable gastric cancer. We investigated the efficacy and feasibility of adjuvant surgery following chemotherapy.Patients and Methods: Records of 70 patients with unresectable stage IV gastric cancer who underwent induction chemotherapy were reviewed retrospectively. Patients who developed an absence of non-curative clinical factors during chemotherapy underwent gastrectomy [adjuvant surgery (AS) group]; the others continued chemotherapy [non-AS group].Results: Non-AS and AS groups contained 56 (80%) and 14 (20%) patients, respectively. In the AS group, 92.9% of patients had one noncurative clinical factor, while 48.2% of patients in the non-AS group had two or more non-curative clinical factors (p=0.0386). In the AS group, operative outcomes, including the postoperative complication rate (21.4%), were acceptable. The 3-year overall survival rate in the AS group was 65.6% versus 7.7% in the non-AS group (p<0.0001). In patients with one noncurative clinical factor of peritoneal dissemination, the median survival of the AS group was 29.5 months versus 11.4 months in the non-AS group (p=0.0230).Conclusion: Adjuvant surgery for initially unresectable stage IV gastric cancer was safe and feasible, and may improve the prognosis for patients with one non-curative clinical factor, such as peritoneal dissemination.

AB - Background: More effective treatment is necessary to improve the poor prognosis for patients with unresectable gastric cancer. We investigated the efficacy and feasibility of adjuvant surgery following chemotherapy.Patients and Methods: Records of 70 patients with unresectable stage IV gastric cancer who underwent induction chemotherapy were reviewed retrospectively. Patients who developed an absence of non-curative clinical factors during chemotherapy underwent gastrectomy [adjuvant surgery (AS) group]; the others continued chemotherapy [non-AS group].Results: Non-AS and AS groups contained 56 (80%) and 14 (20%) patients, respectively. In the AS group, 92.9% of patients had one noncurative clinical factor, while 48.2% of patients in the non-AS group had two or more non-curative clinical factors (p=0.0386). In the AS group, operative outcomes, including the postoperative complication rate (21.4%), were acceptable. The 3-year overall survival rate in the AS group was 65.6% versus 7.7% in the non-AS group (p<0.0001). In patients with one noncurative clinical factor of peritoneal dissemination, the median survival of the AS group was 29.5 months versus 11.4 months in the non-AS group (p=0.0230).Conclusion: Adjuvant surgery for initially unresectable stage IV gastric cancer was safe and feasible, and may improve the prognosis for patients with one non-curative clinical factor, such as peritoneal dissemination.

UR - http://www.scopus.com/inward/record.url?scp=84920392238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920392238&partnerID=8YFLogxK

M3 - Article

C2 - 25550579

AN - SCOPUS:84920392238

VL - 35

SP - 401

EP - 406

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -